Generic Name and Formulations:
Erythromycin (as base) 250mg, 333mg, 500mg; e-c tabs.
Arbor Pharmaceuticals, LLC
Indications for ERY-TAB:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
250mg every 6 hours, 500mg every 12 hours, or 333mg every 8 hours; max 4g/day; twice daily dosing max 1g/day. Legionnaires: 1–4g/day in divided doses.
30–50mg/kg/day in divided doses; max 100mg/kg/day.
Concomitant cisapride, pimozide.
Hepatic dysfunction. Myasthenia gravis. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP450 (eg, carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, disopyramide, bromocriptine, valproate). May potentiate warfarin, triazolam, midazolam, methylprednisolone, digoxin, theophylline, ergotamine. Avoid use with statins (rhabdomyolysis).
GI upset, abdominal pain, anorexia, hepatic dysfunction, rash, superinfection; pseudomembranous colitis, (rare).
250mg—30, 40, 100, 500; 333mg—30, 100, 500; 500mg—100
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Personal Health Information Found in Recycling
- Nightmares in Military Personnel Frequently Comorbid With Mental Health Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Addressing Racial Disparities in Bipolar Disorder Treatment
- Negative Symptoms Increase Cardiovascular Risk in Schizophrenia